AstraZeneca (AZN) ADSs rose after reporting its experimental breast cancer treatment made 🦩with Japanese partner Daiichi Sankyo showed positive high-level results in a Phase 3 trial.

AstraZeneca reported that its datopotamab deruxtecan (Dato-DXd) demonstrated “a statistically significant and clinically meaningful improvement in progression-free survival” for patients with inoperable or metastatic hormone receptor breast cancer who received other treatments.

Susan 🌞Galbraith, executive vice president of oncology research and development at AstraZeneca, called the findings “a significant development” for those🌜 with the most common form of breast cancer whose tumors have become insensitive to endocrine therapy.

Th🐬e companies not꧃ed that plans for global regulatory submissions were underway. They’re also researching the possibility of Dato-DXd as a treatment for lung cancer. 

澳洲幸运5官方开奖结果体彩网:American depositary shares (ADSs) of AstraZeneca rose 2% in early trading as of noon Eastern on Friday following the news, but were 1.4% lower year-to-date.